Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
Why a ‘rip-off’ degree might be worth the money after all – research study 
CDC Monitors U.S. Travelers After Hantavirus Outbreak on Luxury Cruise Ship 
The four types of dementia most people don’t know exist 
Supreme Court Blocks 5th Circuit Ruling on Abortion Pill Access 
South Korea’s KOSPI Jumps Over 5% as Samsung, SK Hynix Rally on Micron Earnings Boost 
Wall Street Ends Mixed as Micron Surges, Apple Drops After Price Hikes 
Iran Attack in Strait of Hormuz Pushes Oil Prices Higher 
Bayer Wins Major U.S. Supreme Court Roundup Lawsuit, Shares Surge 
White House Seeks $1.4 Billion to Combat Growing Ebola Outbreak 
Asian Currencies Trade Mixed as Yen Hovers Near 40-Year Low, Dollar Holds Firm on Fed Outlook 
Australia Jobs Growth Strengthens Rate Hike Outlook 
What’s the difference between baking powder and baking soda? It’s subtle, but significant 
Australian Household Spending Rebounds Strongly in May as Travel and Dining Drive Consumer Growth 
Alphabet Replaces Verizon in Dow Jones Industrial Average 
Why financial hardship is more likely if you’re disabled or sick 
Trip.com Shares Tumble After Q1 Profit Drops and Weak Revenue Growth Outlook 
Coca-Cola Japan and Kirin Holdings will develop health drinks that contain the live bacteria, lactococcus lactis strain plasma (LC-Plasma), an ingredient patented by Kirin that is used in the company's health drinks.
Kirin claims that the live bacteria boosts immunity in healthy people.
Kirin is the first among companies that make foods and beverages they claim to boost immunity to have been approved by Japan's Consumer Affairs Agency in 2020 to advertise its products as such.
Coca-Cola Japan plans to put LC-Plasma into three of its brands, Georgia, Irohasu, and Minute Maid.
The Consumer Affairs Agency has also given the go-ahead for the drinks to be advertised as having the advantage.
The partnership demonstrates Coca-Cola Japan's intention to improve its position in the health beverage market. According to market research firm Inryo Soken, Coca-Cola has a 26 percent market share in soft drinks but has not advanced significantly in the market for health beverages.
On the other hand, Kirin is increasing sales of its LC-Plasma component and sees health products as its next area of growth. It anticipates that by 2027, sales of health drinks will have increased fivefold from their current level to 50 billion yen.
Taisho Pharmaceutical Holdings, as well as candy manufacturers including Morinaga & Co. and Kanro, have already purchased the component from Kirin.
Although supplying a rival with distinctive ingredients would negate Kirin's advantage, collaborating with Coca-Cola might let it expand its market.
